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Background: Dengue fever is the most rapidly spreading mosquito-borne viral disease in the world. Haemophilia A
is the commonest inherited bleeding disorder. There is little data on the incidence and outcome of dengue in
patients with haemophila. We report a case of a patient with severe haemophila A, presenting with dengue fever,
managed at a tertiary care hospital in Sri Lanka.
Case presentation: A 16-year-old Sinhalese male with severe haemophilia A (factor level < 1percent) was admitted
to a teaching hospital in Sri Lanka on day 1 of an acute febrile illness, associated with arthralgia, myalgia, vomiting
and headache. On admission, he had a tachycardia of 120 beats per minute, and blood pressure of 110/70 millimetres
of mercury, with no bleeding manifestations. Baseline investigations revealed leukocyte and platelet counts of 4400
and 241,000 per cubic millimtre, respectively, and a haematocrit of 34.5 percent. Dengue was confirmed later by
sero-conversion of the dengue IgM antibody test. Fluid balance, pulse rate and blood pressure were monitored hourly.
The haematocrit and platelet counts were checked thrice daily, while he was clinically assessed for bleeding. On day
3 he developed bleeding from a tooth extraction site, with vomiting of dark red blood. His platelet level at that point
was 124,000 per cubic millimetre with a haematocrit of 32 percent. Intravenous factor VIII was given to achieve a 100
percent factor correction over twenty-four hours. His platelet count dropped progressively from admission to a nadir of
50,000 per cubic millimetre on day 6. He did not develop clinical evidence of fluid leakage. On day 7 he was discharged
after complete recovery.
Conclusions: People with haemophilia may exhibit bleeding from the early febrile stage and at higher platelet levels
than most other patients with dengue. Further discussion and research is necessary to decide on the optimal
management of these patients, with regard to monitoring and timely treatment with blood products and/or factor
correction, in order to prevent dengue-related morbidity and mortality whilst avoiding overtreatment. In endemic
areas it is advisable that such patients seek early medical help in the event of an acute fever.
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Dengue fever (DF) is a vector borne viral disease caused
by the dengue virus, which belongs to the family filoviri-
dae and genus flavivirus [1]. Currently it is the most rap-
idly spreading mosquito-borne viral disease in the world
[2]. Sri Lanka, is an island nation in the Indian subcon-
tinent that has a population of nearly 20.5 million [3].
DF is endemic in most parts of Sri Lanka, where it ac-
counts for a large proportion of all hospital admissions
with acute fever. In 2011 alone 27,162 cases of DF were
reported in Sri Lanka, with 246 deaths [4]. Dengue has a* Correspondence: dilushi_w@yahoo.com
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clinically unpredictable evolution and outcome. Most
patients with DF recover following a self-limiting non-
severe clinical course, while a small proportion progress
to develop severe disease, characterized by plasma leakage
with or without haemorrhage [2]. Severe thrombocytopenia
and increased vascular permeability are the two major char-
acteristics of dengue hemorrhagic fever (DHF) [5].
Haemophilia A is the most common inherited bleed-
ing disorder, caused by defects in the gene that encodes
coagulation factor VIII. It is an X-linked recessive dis-
order which occurs in approximately 1:5000 males [6].
Patients with pre-existing coagulopathies such as hae-
mophila are probably at a higher risk of bleeding thanntral. This is an Open Access article distributed under the terms of the Creative
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ing at higher platelet counts than the normal population.
There is a scarcity of data on the incidence and outcome
of DF in patients with haemophila [7]. We report a case
of a patient with severe haemophila A (factor level <1%)
presenting with DF, managed at a tertiary care hospital
in Sri Lanka.
Case presentation
A 16-year-old Sinhalese male with severe haemophilia A
(factor level < 1%), was admitted to a teaching hospital in
Sri Lanka on Day 1 of an acute febrile illness. He had been
diagnosed with haemophilia in early childhood, but was
not on prophylactic factor VIII therapy. Four days before
admission, he had undergone a dental extraction, with
30% factor correction with intravenous factor VIII prior to
the procedure. One day before admission he had devel-
oped bleeding from the extraction site, which had been
treated with 750 IU of factor VIII to achieve a 30% factor
correction. On the day of admission he had developed
fever with chills and rigors, associated with arthralgia, my-
algia, nausea, vomiting and severe frontal headache.
On admission, he was febrile and flushed, with a heart
rate of 120 beats per minute and a blood pressure of
110/70 millimetres of mercury. The respiratory rate was
20 per minute, with clear lungs on auscultation. The ab-
domen was soft, with mild epigastric tenderness. Neuro-
logical examination including the fundus examination
was unremarkable. There was no evidence of bleeding
on clinical evaluation at the time of admission.
Baseline investigations revealed a white blood cell
count of 4400 per cubic milimetre (/mm3) (Neutrophils
47%; Lymphocytes 41%), while the platelet count and
haematocrit were 241,000/mm3 and 34.5% (haemoglobin
11.3 g/dl) respectively. The erthyrocyte sedimentation
rate, urine full report, serum creatinine, hepatic tranasa-
minases, prothrombrin time and Chest X-ray were all
within normal limits and remained normal during the
entire hospital stay. A clinical diagnosis of a possible un-
differentiated viral fever or dengue fever (DF) was made
based on the history, examination and investigations.
Subsequently DF was confirmed by sero-conversion with
the dengue IgM antibody test (MAC-ELISA, M Antibody
capture- Enzyme Linked Immunosorbent Assay) on the
tenth day. Earlier confirmation by antigen detection was
not possible due to limited availability of test. He was
managed as dengue, according to the national dengue
management guidelines, with hourly monitoring of fluid
balance, pulse rate and blood pressure [8]. The haemato-
crit and platelet counts were checked thrice per day. The
patient was frequently clinically evaluated to detect the
presence of any bleeding.
On day 2 of the illness he complained of severe throb-
bing headache associated with vomiting. Neurologicalexamination, including fundoscopy, was normal. An ur-
gent non-contrast computerized tomography (CT) scan
of the brain excluded the presence of any intracranial
bleeding. On day 3 of the fever he developed recurrence
of bleeding from the tooth extraction site, together with
vomiting of dark red blood. His platelet level at that
point was 124,000/mm3 with a haematocrit of 32%.
Intravenous factor VIII was given to achieve a 100% fac-
tor correction over twenty four hours. Omeprazole was
administered intravenously for management of possible
co-existing gastric erosions or peptic ulcers. Factor cor-
rection was discontinued after 24 hours (on day 4) as
bleeding had settled and activated partial thromboplastin
time (APTT) was in the normal range. Fever resolved by
day 5. His platelet count dropped progressively from day
1 to a nadir of 50,000/mm3 on day 6. During the course
of the illness he did not develop any clinical evidence of
fluid leakage or become haemodynamically unstable. On
day 7 he was discharged since he was afebrile and clinic-
ally well, with a rising platelet count of 69,000/mm3.
Discussion
People with bleeding disorders such as haemophilia, pre-
senting with dengue infection, have an increased risk of
bleeding compared to non- haemopliliacs [4]. In a series
of 6 cases with DF from Thailand, it was noted that
people with haemophilia exhibited bleeding manifesta-
tions from the early febrile stage and at higher platelet
levels, in contrast to the pattern observed in most other
patients with DF [7]. This is possibly due to the lack of
factor VIII and/or aggravation of bleeding risk due to
the vasculopathy in DF [7] In the case of the current pa-
tient, who had a non-severe form of dengue, his recent
surgical procedure placed him at higher risk of bleeding.
The suspicion of concurrent dengue infection in this
patient was crucial to his optimal monitoring and man-
agement as serious bleeding manifestations could be
expected during the late febrile and critical phases when
thrombocytopenia occurs. The current WHO DF guide-
lines do not emphasise congenital bleeding disorders as
a ‘coexisting condition’ that necessitates admission, or
provide special guidance on monitoring and managing
such patients [2]. Considering the higher risk of bleed-
ing, and the chance that bleeding may occur earlier on
in disease than in non-haemophiliacs, closer clinical and
haematological monitoring may be required than is rec-
ommended for non-haemophiliacs.
Further discussion and research is necessary to decide
on the optimal management of these patients, especially
with regards to monitoring protocols and the requirement
and timing of blood products and/or factor correction. In
the current patient, it was decided to achieve a 100%
factor correction with the appearance of mild bleeding
while monitoring APTT. The place of prophylactic factor
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not clearly understood. While under-correction poses a
risk of bleeding, indiscriminate factor replacement places
the patient at a risk of side effects, and is extremely expen-
sive [9]. Hence, there is an urgent necessity for evidence-
based and/or interdisciplinary consensus-based guidelines
on the management of DF in patients with bleeding disor-
ders such as haemophilia. In endemic areas such as in Sri
Lanka it is advisable for patients with haemophilia to seek
early medical help in the event of an acute fever. As most
patients with congenital bleeding disorders are regularly
followed up at hospital clinics, education in this regard
can be easily achieved.
Conclusion
People with haemophilia who develop dengue virus in-
fections may exhibit bleeding manifestations from the
early febrile stage and at higher platelet levels, compared
to the pattern observed in most non-haemophiliac pa-
tients with dengue fever. Further discussion and research
is necessary to decide on the optimal management of
these patients, with regard to monitoring and timely
treatment with blood products and/or factor correction,
in order to prevent dengue related morbidity and mor-
tality whilst avoiding overtreatment. In dengue endemic
areas it is advisable that patients with bleeding disorders
such as haemophilia seek early medical help in the event
of an acute fever.
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